Integrated infusion container

• US 10,258,539 B2
• Filed: 03/24/2016
• Issued: 04/16/2019
• Est. Priority Date: 06/28/2005
• Status: Active Grant

• Current Assignee: BNCP Corporation
• Original Assignee: BNCP Corporation
• Inventors: Oh, Gi-Bum
• Primary Examiner(s): Zalukeava, Tatyana
• Assistant Examiner(s): Burnette, Gabriella
• Application Number:
  US15/080,210
• Publication Number:
  US 20160199259A1
• Time in Patent Office: 1,118 Days
• Field of Search: 604414, 604416
• CPC Class Codes: A61J 1/10 Bag-type containers
• CPC Class Codes: A61J 1/1462 Containers with provisions for hanging, e.g. integral adaptations of the container accessories for hanging the container A61M5/1414
• CPC Class Codes: A61J 1/201 having one piercing end
• CPC Class Codes: A61J 1/2051 having tap means, e.g. tap means activated by sliding
• CPC Class Codes: A61J 1/2065 having aligning and guiding means
• CPC Class Codes: A61J 1/2089 Containers or vials which are to be joined to each other in order to mix their contents combinations of vial and syringe for mixing their contents A61J1/2096
• CPC Class Codes: A61K 31/341 not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• CPC Class Codes: A61K 31/397 having four-membered rings, e.g. azetidine
• CPC Class Codes: A61K 31/407 condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
• CPC Class Codes: A61K 31/426 1,3-Thiazoles
• CPC Class Codes: A61K 31/43 Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
• CPC Class Codes: A61K 31/513 having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• CPC Class Codes: A61K 31/5365 ortho- or peri-condensed with heterocyclic ring systems
• CPC Class Codes: A61K 31/546 containing further heterocyclic rings, e.g. cephalothin
• CPC Class Codes: A61K 38/482 Serine endopeptidases (3.4.21)
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: C12Y 304/21073 u-Plasminogen activator (3.4.21.73), i.e. urokinase

Abstract

The present invention relates to unitary bottle for injection, more particularly, to a unitary medicine bottle having an integral structure where a medicine container is easily connected with a plastic container including a solution at a completely sterilized state so that powdered, freeze-dried or liquid medicine is mixed with the solution with one touch for a short time. The unitary medicine bottle for injection according to the present invention comprises: a plastic container equipped with a coupling member connected with a medicine container at one end and a releasing member for releasing a liquid medicine to be at the other end; a protection cap integrally formed with the coupling member to accept the medicine container; and a flue needle which moves forward in a direction of the medicine container and perforates a stopper of the medicine container and is inserted in the coupling member connecting the plastic container with the medicine container.

Claims

1. A unitary medicine bottle kit for injection comprising:

a coupling member;

a plastic container at a first end of the coupling member;

a medicine container at a second end of the coupling member;

a cap connected to the second end of the coupling member to accept the medicine container;

a flue needle;

a flange;

a releasing member; and

a medicine inside the medicine container,

wherein,

the plastic container has a first end and a second end, the coupling member is at the first end of the plastic container, the releasing member is at the second end of the plastic container, and the first end of the plastic container is opposite the second end of the plastic container;

the medicine container is penetrable;

the cap comprises;

a fixing cap which is one body with the coupling member;

a moving cap interpolated within the fixing cap for altering the size of an aseptic interior space when the moving cap moves;

the flue needle is inserted into the coupling member, and the coupling member is fixed in reference to the plastic container and in reference to the fixing cap, wherein the flue needle moves towards the medicine container, penetrating the medicine container independently of the medicine container;

the medicine container is equipped with a stopper configured to be penetrated by the flue needle; and

the flange comprises;

a fixing flange; and

a moving flange;

wherein the moving flange and the fixing flange are aligned with each other and conform to each other at an end of the fixing cap, and the moving flange is attached to the moving cap and the fixing flange is fixed on the fixing cap to set the aseptic interior space; and

the coupling member and the stopper are in direct contact when the stopper is pierced.

2. The unitary medicine bottle kit of claim 1, wherein the medicine comprises a cephem series antibiotic.

3. The unitary medicine bottle kit of claim 2, wherein the cephem series antibiotic is selected from the group consisting of cefazolin sodium, ceftizoxime sodium, and cefotiam hydrochloride.

4. The unitary medicine bottle kit of claim 1, wherein the medicine comprises a penicillin series antibiotic.

5. The unitary medicine bottle kit of claim 4, wherein the penicillin series pre-antibiotic is selected from the group consisting of ampicillin sodium and penicillin sodium.

6. The unitary medicine bottle kit of claim 1, wherein the medicine comprises a carbapenum series antibiotic.

7. The unitary medicine bottle kit of claim 6, wherein the carbapenum series antibiotic is imipenem.

8. The unitary medicine bottle kit of claim 1, wherein the medicine comprises an antibiotic.

9. The unitary medicine bottle kit of claim 8, wherein the antibiotic is mitomycine C.

10. The unitary medicine bottle kit of claim 8, wherein the antibiotic is fluorourcil.

11. The unitary medicine bottle kit of claim 1, wherein the medicine comprises an antiulcer agent.

12. The unitary medicine bottle kit of claim 11, wherein the antiulcer agent is famotidine.

13. The unitary medicine bottle kit of claim 11, wherein the antiulcer agent is hydrochloric acid ranitidine.

14. The unitary medicine bottle kit of claim 1 wherein the medicine comprises a thrombosis solvent.

15. The unitary medicine bottle kit of claim 14, wherein the thrombosis solvent is urokinase.

16. The unitary medicine bottle kit of claim 14, wherein the thrombosis solvent is flomoxef sodium.